Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + SOX for Locally Advanced Gastric/GEJ Adenocarcinoma
NCT06764251Phase 2Not yet recruiting
- Sponsor
- Liaoning Medical Center
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Liaoning Medical Center. Primary endpoint: Pathologic Complete Response Rate at 3 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06764251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764251.